Mild hyperthermia therapy (HT), which involves heating tumors to below 43 °C for about one hour, has emerged as a potent radiosensitizer.[32, 33] Early studies primarily attributed the sensitizing effects of HT to direct thermal damage and reduced tumor hypoxia.[33] However, more recent investigations have revealed that HT also disrupts key proteins involved in the NHEJ and HR repair pathways.[34] Building on this understanding, combining HT with RT holds promise for significantly enhancing DNA damage, inducing ICD, and activating the cGAS‐STING pathway. The gene discussed is STING1; the disease is neoplasm.